Nanopath Grows Its Leadership Team to Enhance Scientific and Commercial Potential
Nanopath Expands Leadership Team to Drive Next Phase of Scientific and Commercial Growth
CAMBRIDGE, Mass., Oct. 16, 2025 — Nanopath, a pioneering company in point-of-care diagnostics that enables rapid, high-quality molecular testing, has just announced exciting developments in its leadership team. This strategic expansion includes five experts who are set to guide the company through its next growth phase.
Nanopath is dedicated to revolutionizing healthcare, particularly in women's health, and these new appointments will significantly strengthen their efforts to bring innovative solutions to the market. The additions come as the company reflects its commitment to not only technological advancement but also to fostering a collaborative and impactful company culture.
New Leadership Appointments
Alison Burklund, Ph.D., Co-Founder and Co-CEO of Nanopath, expressed great enthusiasm over these new team members: "These individuals are not only experts in their fields but also collaborative leaders who embody our mission and culture."
1. Dr. Edward Evantash - Chief Medical Officer: Dr. Evantash will spearhead the clinical strategy for Nanopath, ensuring that their innovative testing methods translate effectively into patient care. He brings over a decade of experience as Medical Director at Hologic, with a strong background in obstetrics and gynecology. His confidence in Nanopath's mission is palpable: "I'm incredibly excited to join team Nanopath! This platform is set to establish a new standard of care."
2. Dr. Matthew Black - Chief Scientific Officer: Formerly the leader of Nanopath's Assay Development Team, Dr. Black's new role as Chief Scientific Officer recognizes his groundbreaking work in driving platform advancements. Having previously developed the first FDA-authorized at-home COVID-19 molecular test, his insights are invaluable. "I'm proud to redefine how we deliver fast, accurate molecular testing closer to patients," he stated.
3. Matt Cote - Vice President of Engineering: Mr. Cote has already made significant contributions to Nanopath's engineering prowess. His innovative designs aim to enhance the usability and performance of the company’s cartridge-reader system. With experience from Quanterix, Cote's engineering background is set to further advance Nanopath's technology.
4. Madeleine Livingston - Strategic Women's Health Advisor: Ms. Livingston will sharpen the focus on women's health initiatives and guide strategic partnerships for maximum clinical impact. With a wealth of experience in mobilizing stakeholders in the health sector, including initiatives with the Gates Foundation, her role is crucial for Nanopath's growth trajectory.
5. Dr. Christopher Slachta - Operations & Manufacturing Advisor: As Nanopath transitions from development to production, Dr. Slachta’s extensive experience in medical diagnostics will be essential. His past roles include COO at Cytovale and leadership positions at Abbott, bringing the expertise needed to streamline manufacturing processes.
A Thriving Environment for Growth
The timing of these new appointments aligns perfectly with the momentum Nanopath has been building. Over the past year, the company has doubled its workforce from 13 to 20 employees, reflecting significant growth across various sectors, including product development and pilot clinical studies.
Amogha Tadimety, Ph.D., Co-Founder and Co-CEO, expressed optimism about the future: "Our new leadership will drive our mission forward to transform diagnostics in women's health and beyond. Together, with our dedicated interdisciplinary team, we are poised for substantial advancements."
About Nanopath
Nanopath is an innovative, women-led enterprise committed to advancing health equity globally, beginning with women’s health. Their proprietary molecular diagnostic platform employs cutting-edge biosensing technology to conduct complex tests on-site, rather than in centralized labs. Headquartered in Cambridge, Massachusetts, at MIT's The Engine, Nanopath is positioning itself at the forefront of diagnostics innovation, supported by esteemed backers such as Norwest Venture Partners and the Medtech Convergence Fund. To learn more about Nanopath's mission and technology, please visit www.nanopath.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.